CU Medicine’s Microbiome Immunity Formula Offers Hope to Boost Immunity
(Left) Dr. Joyce MAK, Assistant Professor of the Division of Gastroenterology and Hepatology at the Department of Medicine and Therapeutics; Professor Siew NG, Associate Director of the Centre for Gut Microbiota Research; and Professor Francis CHAN, Dean of Medicine and Director of the Centre for Gut Microbiota Research; CUHK.
Gut microbiota plays an important role in regulating immunity against infections. People who suffer from imbalance in gut microbiota (dysbiosis) are more susceptible to viral infection and other complications. An earlier study CU Medicine has highlighted that severe gut dysbiosis exists in COVID-19 patients.
A recent study by CU Medicine revealed a worrying fact that 40% of Hong Kong people appeared to have significant gut dysbiosis comparable to that of COVID-19 patients, suggesting they have potentially impaired immunity. CU Medicine has developed a microbiome immunity formula that targets gut dysbiosis. Compared with patients who had standard care, our research team found that more COVID-19 patients who received the microbiome immunity formula achieved complete symptom resolution, showed significantly reduced proinflammatory markers in their blood, had increased favourable bacteria in their stool; and developed neutralising antibody. Data also suggested that the formula can restore the balance of gut microbiota and boosts immunity.